Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm

This article was originally published in The Gray Sheet

Executive Summary

High court rules the processes covered by two patents to determine proper drug dosages based on metabolite concentrations do not transform unpatentable natural laws into patent-eligible applications.

You may also be interested in...



'Alice' In Patent Land: Finding Patentable Digital Health Innovations Is No Easy Task

While the mobile health sector and digital health in general is poised for a major boom, a 2014 case, Alice Corp. v. CLS Bank International, continues to be a major hurdle for manufacturers wanting to patent their software. While there are some recent positive trends, attorneys recommend caution and proactive steps to make the best of the current patent environment.

Patent Office Guidance Oversteps Myriad Court Decision, Industry Argues

Development of products derived from natural sources will be deterred by PTO’s factor-based approach to patent eligibility, firms contend, noting special concern about examples given in the office’s recent guidance document.

2013: The Year In Diagnostics

Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel